Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year.

“Jeff is the ideal person to introduce Motiva to the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. “Just as we have changed the standard for breast augmentation and reconstruction around the world for more than a decade, we will establish a new standard for women and plastic surgeons in the United States. With Jeff leading our efforts, we expect to become the leading technology not only in the U.S., but globally."

Mr. Ehrhardt was most recently General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics. In his most recent role, Jeff was responsible for the company’s portfolio of implants and related technologies in breast augmentation and reconstruction, including developing and executing the group’s commercial strategy and managing the U.S. sales and marketing organizations. He has held a number of other positions at Allergan, including vice president of U.S. operations, vice president of sales, regional sales director, marketing director, sales training director, sales rep, and roles in business development. Prior to Allergan, Mr. Ehrhardt also worked at American Cyanamid and Johnson & Johnson. Mr. Ehrhardt received his bachelor’s degree in business from the University of Cincinnati and his MBA from Xavier University.

"Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” said Jeff Ehrhardt. “I’ve seen firsthand the diminished importance of science and data in the U.S. market. The lack of innovation has left plastic surgeons with few, if any, real choices for technologies that can improve the outcomes of their breast procedures. Establishment Labs is different. The quality of the science and the outcomes achieved with Motiva implants are unprecedented. We will not only take share, but also have the potential to grow these markets as we show what can be achieved when a company puts women at the center of everything that it does.”